| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 02/02/2006 | US20060024237 Fine, warm, dripless, non-irritating spray; tasteless, odorless, non-aqueous liquid; Suitably the carrier is a cyclopentasiloxane, preferably decamethylcyclopentylsiloxane, a triglyceride, a diglyceride, and mixtures of said glycerides |
| 02/02/2006 | US20060024233 Use of biomolecular targets in the treatment and visualization of brain tumors |
| 02/02/2006 | US20060024232 Imaging and therapeutic agents targeting proteins expressed on endothelial cell surface |
| 02/02/2006 | US20060024231 Tissue-specific imaging and therapeutic agents targeting proteins expressed on lung endothelial cell surface |
| 02/02/2006 | US20060024230 Customized therapeutics and in situ diagnostics |
| 02/02/2006 | CA2617188A1 Antimicrobial and/or antiviral composition and to methods for preparing and administering same |
| 02/02/2006 | CA2617185A1 Skin coating composition and uses thereof |
| 02/02/2006 | CA2574664A1 Compound formulations of 2-amino-1,3-propanediol compounds |
| 02/02/2006 | CA2574124A1 Carrier for medicaments for obtaining oral bioavailability |
| 02/02/2006 | CA2571926A1 Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions |
| 02/01/2006 | EP1621569A1 Polyethylene glycol/polycation block copolymer |
| 02/01/2006 | EP1621212A1 Formulations comprising antisense nucleotides to connexins |
| 02/01/2006 | EP1621206A1 Chimeric cytokines and uses thereof |
| 02/01/2006 | EP1621202A1 Freeze-dried preparation containing methylcobalamin and process for producing the same |
| 02/01/2006 | EP1621199A1 Remedies for diseases to be applied to eye |
| 02/01/2006 | EP1621197A2 Composition comprising a steroid and an anticholinergic agent |
| 02/01/2006 | EP1621194A1 Active oxygen eliminator originating in natural material and use of the same |
| 02/01/2006 | EP1621188A1 Ultraviolet-shielding type patch |
| 02/01/2006 | EP1620734A1 Secreted polypeptide species reduced cardiovascular disorders |
| 02/01/2006 | EP1620547A2 Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics |
| 02/01/2006 | EP1620140A1 Injectable cross-linked polymeric preparations and uses thereof |
| 02/01/2006 | EP1620130A1 Prodrugs cleavable by cd26 |
| 02/01/2006 | EP1620118A2 Reversible pegylated drugs |
| 02/01/2006 | EP1620114A2 Delivery systems of homogeneous thermoreversible low viscosity polymannan gum films |
| 02/01/2006 | EP1620110A2 Immunomodulator phosphonate conjugates |
| 02/01/2006 | EP1620109A2 Kinase inhibitor phosphonate conjugates |
| 02/01/2006 | EP1620079A1 Bone targeting of biodegradable drug-containing nanoparticles |
| 02/01/2006 | EP1620073A1 Absorption enhancers such as e.g. bht, bha or propyl gallate |
| 02/01/2006 | EP1620072A1 Zinc-containing sustained-release composition, its preparation, and method for producing the same |
| 02/01/2006 | EP1620069A2 Warning and nonirritating lubricant fungicide compositions in the form of a gel |
| 02/01/2006 | EP1620059A2 Delivery systems of homogeneous, thermoreversible gel film containing kappa-2 carrageenan |
| 02/01/2006 | EP1521535B1 Improved bulking agent composition |
| 02/01/2006 | EP1509202A4 Novel high viscosity embolizing compositions comprising prepolymers |
| 02/01/2006 | EP1487421B1 Pharmaceutical formulation for the active ingredient budesonide |
| 02/01/2006 | EP1343492B1 Treatment of mucositis |
| 02/01/2006 | EP1328266B1 Combination of fenofibrate and coenzyme q10 for the treatment of endothelial dysfunction |
| 02/01/2006 | EP1267827B1 Use of an aqueous solution for the treatment of try eye |
| 02/01/2006 | EP1225874B1 Antiviral solid dispersions |
| 02/01/2006 | EP1150675B1 A transdermal composition of an antivomiting agent and a preparation containing the same |
| 02/01/2006 | EP1104289B1 New oral formulation for 5-ht4 agonists or antagonists |
| 02/01/2006 | EP1001743B1 Implants for controlled release of pharmaceutically active principles and method for making same |
| 02/01/2006 | EP0885060B1 Solid or semi-solid hydrocarbon gels |
| 02/01/2006 | CN1729202A Targeting single epitopes |
| 02/01/2006 | CN1729018A G-CSF conjugates |
| 02/01/2006 | CN1729015A Long acting erythropoietins that maintain tissue protective activity of endogenous erythropoietin |
| 02/01/2006 | CN1729013A Broad spectrum anti-viral therapeutics and prophylaxis |
| 02/01/2006 | CN1729011A Improved pharmaceutical botulinum toxin compositions |
| 02/01/2006 | CN1729002A Exemestane as chemopreventing agent |
| 02/01/2006 | CN1728995A Dosage forms comprising a cetp inhibitor and an HMG-CoA reductase inhibitor |
| 02/01/2006 | CN1728993A Pharmaceutical composition comprising lumiracoxib |
| 02/01/2006 | CN1728984A Dosing aerosols containing lecithin as a surface-active substance |
| 02/01/2006 | CN1728983A Process for the chemical stabilization of a solubilized retinoid in a solvent using a base |
| 02/01/2006 | CN1727004A Slow release implantation system for injectable calcium sulphate based medication |
| 02/01/2006 | CN1727003A Carcinogen detoxification composition and method |
| 02/01/2006 | CN1727002A Compound bioogic component and pharmaceutical preparation possessing function for accelerating hemoglutination |
| 02/01/2006 | CN1727001A Method of preparing system for controlled release of medication in protein category |
| 02/01/2006 | CN1239204C Conjugates useful in treatment of prostate cancer |
| 02/01/2006 | CN1239203C Hydrogel composition for transdermal drug delivery |
| 02/01/2006 | CN1239202C Intelligent medicine release system and its preparation and usage |
| 02/01/2006 | CN1239178C Method for preparing qingkailing granules |
| 02/01/2006 | CN1239158C 2-methyl-thieno-benzodiazepine formulation |
| 02/01/2006 | CN1239153C Transdermal therapeutic system based on polyacrylate-contact-bonding adhesives without functional groups |
| 02/01/2006 | CN1239151C Tablets quickly disintegrating in oral cavity |
| 02/01/2006 | CN1239149C Pharmaceutical formulation having masked taste and method for production thereof |
| 01/31/2006 | US6992218 Method for obtaining aqueous formulations of oxidation-sensitive active principles |
| 01/31/2006 | US6992180 Oligo- or polynucleotides comprising phosphate-moiety labeled nucleotides |
| 01/31/2006 | US6992176 Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease |
| 01/31/2006 | US6992174 Reducing the immunogenicity of fusion proteins |
| 01/31/2006 | US6992169 Drug moiety linked to a carrier moiety comprising a homeobox peptide or a fragment or derivative thereof. |
| 01/31/2006 | US6992168 Sterically hindered poly(ethylene glycol) alkanoic acids and derivatives thereof |
| 01/31/2006 | US6992076 Providing sustained systemic concentrations of therapeutic or prophylactic agents such as gamma-aminobutyric acid derivatives following oral adiminstration to animals |
| 01/31/2006 | US6992070 Treating tissue with phosphodiesterase inhibitor compound and administering exogenous nucleic acid |
| 01/31/2006 | US6992066 Povidone-containing carriers for polypeptide growth factors |
| 01/31/2006 | US6992065 Sustained release formulations |
| 01/31/2006 | US6991901 Administering an antibody to the polypeptide sec1; angiogenesis inhibitors |
| 01/31/2006 | US6991806 Pharmaceutical compositions comprising ibuprofen and domperidone |
| 01/31/2006 | US6991804 Delivery systems for periadventitial delivery for treatment of restenosis and anastomotic intimal hyperplasia |
| 01/31/2006 | US6991800 containing an echinocandin antifungal compound and an aqueous solvent, wherein the formulation includes about 20% w/v ethanol; extended shelf life, improved solubility |
| 01/31/2006 | US6991776 Halogenated xanthene or halogenated xanthene derivative; cancer treatment |
| 01/31/2006 | US6991775 Peptide-based multimeric targeted contrast agents |
| 01/31/2006 | CA2490335C Pharmaceutical composition as solid dosage form and method for manufacturing thereof |
| 01/31/2006 | CA2371836C Porous drug matrices and methods of manufacture thereof |
| 01/31/2006 | CA2171627C Rectally-administered, epileptic-seizure-inhibiting composition |
| 01/31/2006 | CA2150803C Controlled release growth hormone containing microspheres |
| 01/31/2006 | CA2133012C Pulverulent mannitol of moderate friability and process for its preparation |
| 01/31/2006 | CA2067365C Illudin analogs as anti-tumor agents |
| 01/26/2006 | WO2006010057A2 Therapeutic peptides |
| 01/26/2006 | WO2006010054A2 Multivalent vla-4 antagonists comprising polyethylene glycol moieties |
| 01/26/2006 | WO2006009764A1 Controlled release formulations of enzymes, microorganisms, and antibodies with mucoadhesive polymers |
| 01/26/2006 | WO2006009682A2 Glue compositions for lung volume reduction |
| 01/26/2006 | WO2006009101A1 Contact lens fitting liquid |
| 01/26/2006 | WO2006009022A1 Liposome-containing x-ray radiopaque dye and process for producing the same |
| 01/26/2006 | WO2006008386A1 Bioactive biomaterials for controlled delivery of active principles |
| 01/26/2006 | WO2006008179A2 Cyanine dyes conjugated with antibodies for the diagnosis of micrometastasis |
| 01/26/2006 | WO2006008173A2 Pharmaceutical formulations for inhalation |
| 01/26/2006 | WO2006008092A1 Use of a steroid for enhancement of skin permeability |
| 01/26/2006 | WO2005112996B1 1,4 o-linked saccharose derivatives for stabilizing antibodies or antibody derivatives |
| 01/26/2006 | WO2005110002A3 Anti-inflammatory and anticeptic suppository exhibiting a regeneration effect |
| 01/26/2006 | WO2005094384A3 Methods and compositions for treatment of ion imbalances |
| 01/26/2006 | WO2005079747A8 Pharmaceutical preparation for the oral cavity |